Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2015

View Archived Issues

AstraZeneca reflects on achievements of fourth quarter 2014

bioCSL to sell ALK allergy products in Australia and New Zealand

GlaxoSmithKline presents milestones of fourth quarter 2014

Trevena reports data from phase I study of TRV-734 for acute and chronic pain

Preclinical data suggest utility of ANAVEX 2-73 for epilepsy

Aurinia plans pilot biomarker study of voclosporin in lupus nephritis

Inflection Biosciences and Multiple Myeloma Research Foundation collaborate on IBL-202

Aduro Biotech initiates IND-enabling studies and achieves milestone in Janssen collaboration

Takeda reflects on accomplishments of third quarter of fiscal 2014

SGX-943 shows promising results for melioidosis

AB Science provides update on futility test for masitinib in Alzheimer's disease

Anthera Pharmaceuticals reports on interim analysis from blisibimod trial in SLE

NDA filed for ibandronate sodium hydrate in Japan

Shanghai Fochon Pharmaceutical patents EFGR/HER2 inhibitors for cancer

Chinese companies develop paliperidone amino acid derivatives

Novartis reports autotaxin inhibitors

Epizyme patent divulges EZH2 inhibitors

Otsuka Pharmaceutical patents citric acid cycle activators

Solithromycin protects against tularemia in non-human primate model

FDA expands clearance for Nanotherapeutics bone filler to use in spinal fusion surgery

Cellular Biomedicine Group acquires CAR-T therapy and IP from Chinese PLA General Hospital

FDA approves MediciNova's protocol for phase II trial of tipelukast in IPF

New phase IIa study investigates FRM-0334 for frontotemporal dementia with GRN mutation

Pfenex and Hospira to collaborate on Lucentis biosimilar

JCR begins clinical study of biosimilar for Fabry's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...